Revelation Biosciences, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Revelation Biosciences CEO James Rolke sold 10,115 shares to cover mandatory tax withholding obligations related to restricted stock vesting.
NASDAQ
Revelation Biosciences CFO Chester S. Zygmont III reported the sale of 13,285 shares to satisfy tax obligations related to restricted stock vesting.
NASDAQ
Revelation Biosciences Director Jess Roper sold 1,591 shares of common stock at a weighted average price of $1.85 to cover tax obligations following a restricted stock award vesting.
NASDAQ
Revelation Biosciences Director Lakhmir S Chawla sold 2,261 shares of common stock to cover tax obligations following a restricted stock award vesting.
NASDAQ
Revelation Biosciences Director Jennifer Carver sold 1,661 shares of common stock to cover tax liabilities from restricted stock vesting, following a 1-for-4 reverse stock split.
NASDAQ
Revelation Biosciences CEO James Rolke disposed of 8,521 common shares to cover tax withholding obligations following a 1-for-4 reverse stock split.
NASDAQ
Revelation Biosciences CFO Chester Zygmont III sold 13,100 shares of common stock to cover tax withholding obligations following a restricted stock award vesting.
NASDAQ
Revelation Biosciences CEO James Rolke acquired 532,829 shares of common stock through a restricted stock unit grant, increasing his direct beneficial ownership to 933,489 shares.
NASDAQ
Revelation Biosciences' CFO, Chester S. Zygmont III, acquired 78,145 restricted stock units at $0.90 per share, increasing his indirect beneficial ownership.
NASDAQ
Revelation Biosciences Director Jennifer Carver acquired 41,981 shares of common stock through a restricted stock unit grant.
NASDAQ
Revelation Biosciences Director Jess Roper acquired 41,981 shares of common stock at $0.90 per share, increasing total beneficial ownership to 57,667 shares.
NASDAQ
Revelation Biosciences Director Lakhmir S Chawla acquired 41,981 shares of common stock at $0.90 per share, increasing direct beneficial ownership to 57,667 shares.
NASDAQ
REVELATION BIOSCIENCES Director Lakhmir S Chawla acquired 15,625 shares of common stock through a restricted stock grant.
NASDAQ
Revelation Biosciences CEO James Rolke acquired 390,614 shares of common stock through a restricted stock grant, increasing his direct beneficial ownership.
NASDAQ
REVELATION BIOSCIENCES Director Jennifer Carver acquired 15,625 shares of common stock at $1.28 per share through a restricted stock grant.
NASDAQ
Revelation Biosciences CFO Chester S. Zygmont III was granted 390,614 shares of common stock valued at $1.28 per share.
NASDAQ
Revelation Biosciences Director Jess Roper reported the future acquisition of 15,625 shares of common stock at $1.28 per share through a restricted stock grant.
NASDAQ
Director Lakhmir S Chawla reports acquisition of Revelation Biosciences shares on February 11, 2025.
NASDAQ
Jennifer Carver, a director at Revelation Biosciences, acquired 181 shares of common stock at $3.87 per share on February 11, 2025.
NASDAQ
Director Jess Roper acquired 181 shares of Revelation Biosciences, Inc. at $3.87 per share on February 11, 2025.
NASDAQ
James Rolke, CEO of Revelation Biosciences, reports acquisition of company stock via a restricted stock grant.
NASDAQ
Chester Stanley Zygmont III, CFO of Revelation Biosciences, acquired 15,048 shares of common stock at $3.87 per share on February 11, 2025, through a restricted stock grant.
NASDAQ
George F. Tidmarsh, a director at Revelation Biosciences, acquired additional shares of common stock through a trust and a restricted stock grant.